|1.||Brismar, Kerstin: 19 articles (12/2015 - 04/2004)|
|2.||Pollak, Michael N: 14 articles (05/2015 - 05/2003)|
|3.||Kaaks, Rudolf: 14 articles (03/2011 - 05/2002)|
|4.||Brismar, K: 12 articles (06/2013 - 03/2000)|
|5.||Rinaldi, Sabina: 11 articles (03/2011 - 05/2002)|
|6.||Riboli, Elio: 10 articles (03/2011 - 05/2002)|
|7.||Frystyk, Jan: 9 articles (11/2015 - 10/2003)|
|8.||Flyvbjerg, Allan: 8 articles (11/2015 - 01/2004)|
|9.||Peeters, Petra H M: 7 articles (03/2011 - 08/2003)|
|10.||Lacinová, Z: 7 articles (01/2006 - 08/2001)|
|1.||Body Weight (Weight, Body)
11/01/1995 - "IGFBP-1 administration was, however, associated with a significantly greater loss of body weight (P < 0.05), indicating that the peptide had a profound metabolic effect. "
01/01/2006 - "Plasma IGFBP-1 was measured in individually tagged 1-year-old coho salmon reared for 10 weeks under four different feeding regimes as follows: high constant (2% body weight/day), medium constant (1% body weight/day), high variable (2% to 0.5% body weight/day) and medium variable (1% to 0.5% body weight/day). "
07/01/1997 - "In addition, body weight in adult mice was negatively correlated to plasma concentrations of IGFBP-1 (r = 0.7, P < 0.0001). "
01/01/1993 - "Serum IGF binding activity and levels of IGFBP-1 also are high in the hypoinsulinemic SGA fetal rat and levels of IGFBP-1 correlate with fetal liver and body weight, indicating that IGFBP-1 contributes to the regulation of somatic growth in utero. "
09/01/2010 - "We found that serum IGF-I during pregnancy was positively correlated with maternal body weight (r 0.47-0.56) and fat-free body weight (r 0.61-0.65), whereas serum IGFBP-1 was negatively correlated with maternal body weight (r - 0.44 to - 0.69) and body fat (r - 0.64 to - 0.76) before and during pregnancy. "
|2.||Critical Illness (Critically Ill)
12/01/2001 - "Initial evidence suggests that the level of IGFBP-1 may be predictive of outcome in critically ill patients, suggesting a possible prognostic role for this protein."
04/01/2008 - "High levels of IGFBP-1 are encountered in critically ill patients and are a good predictor marker in acute myocardial infarction. "
06/01/2003 - "A lethal outcome of critical illness is predicted by a high serum concentration of IGFBP-1, pointing to impaired insulin effect rather than pituitary function, and survival was recently shown to be dramatically improved by strict normalization of glycemia with exogenous insulin. "
10/01/2002 - "A lethal outcome of critical illness is predicted by a high serum concentration of IGF-binding protein 1, pointing to impaired insulin effect rather than pituitary function, and survival was recently shown to be dramatically improved by strict normalization of glycemia with exogenous insulin. "
01/01/2002 - "Protein turnover but not lipolysis correlated with a persisting critically ill condition, serum prealbumin, RBP, and plasma IGFBP-1."
04/01/2015 - "The intention of this work was to systematically study the presence of insulin-like growth factor-binding protein 1 and 2 (IGFBP-1 and IGFBP-2) complexes with alpha-2-macroglobulin (α2M) in the circulation of patients with various types of cancer. "
05/01/2015 - "In contrast, IGFBP-1 protein expression was low in MMTV-Neu tumors regardless of Mmp9 status. "
06/01/2012 - "The adjusted hazard ratio per sd of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). "
08/01/2002 - "Moreover, IGFBP-1 could have dual effects on cancer cell motility by disrupting both receptor systems."
04/01/2001 - "The results suggest cell type-specific accumulation of IGFBP-1, -2, and -3 in human glial tumors of the brain. "
01/01/2015 - "The aim of this study was to evaluate the clinical application of a novel method immunomagnetic reduction (IMR) for quantitative measurement of IGFBP-1 concentrations in the cervicovaginal secretions to diagnose pregnant women with preterm premature rupture of membranes (PPROM). "
05/01/2013 - "The aim of this study was to compare the performance of tests based on the detection of insulin-like growth factor binding protein 1 (IGFBP-1) and placental α-microglobulin-1 (PAMG-1) in diagnosing rupture of fetal membranes (ROM) across different patient populations. "
12/01/2013 - "Premature preterm rupture of the membrane diagnosis in early pregnancy: PAMG-1 and IGFBP-1 detection in amniotic fluid with biochemical tests."
11/01/1999 - "[Insulin-like growth factor binding protein 1 (IGFBP-1) in vaginal secretion as a marker of premature rupture of amniotic membranes]."
12/01/1998 - "A PROM test [dipstick detecting IGFBP-1 with a cutoff value of 25 micrograms/l (A)], a BTB test (B), a ROM-Check (C), and a fern test (D) were compared in diagnosing ruptures of the membranes in 48 patients. "
|5.||Prostatic Neoplasms (Prostate Cancer)
12/01/2011 - "Circulating insulin-like growth factor binding protein 1 (IGFBP1) levels vary in response to nutritional status, and pre-clinical studies suggest that elevated IGFBP1 may be protective against the development and progression of prostate cancer. "
05/15/2015 - "In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. "
02/01/2014 - "Elevated IGFBP-1 appears to be associated with shorter time to CRPC and lower overall survival in men with metastatic prostate cancer."
06/01/2001 - "Similarly, IGFBP-1 was inversely associated with prostate cancer risk only among men with the ff FokI genotype (odds ratio, 0.25; 95% confidence interval, 0.07-0.85; P(trend) = 0.02). "
09/01/2000 - "Expression of the IGF system, except IGFBP-1, was detected in all prostate cancer tissue samples. "
|1.||Insulin-Like Growth Factor I (IGF-1)
|4.||Insulin-Like Growth Factor Binding Protein 3
|5.||Insulin-Like Growth Factor Binding Proteins
|7.||Proteins (Proteins, Gene)
|1.||Drug Therapy (Chemotherapy)
|2.||Renal Dialysis (Hemodialysis)
|4.||Heterologous Transplantation (Xenotransplantation)